[A23-58] Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V
Last updated 02.10.2023
Commission awarded on 30.06.2023 by the Federal Joint Committee (G-BA).
Treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.